Researchers Identify Factors Associated With CAR-T Resistance in B-ALL
Dr Orentas discusses CAR-T resistance in patients with B-cell acute lymphoblastic leukemia (B-ALL) and results from an analysis presented at the 2019 ASH Annual Meeting.
For press inquiries, please contact press@seattlechildrens.org.
Dr Orentas discusses CAR-T resistance in patients with B-cell acute lymphoblastic leukemia (B-ALL) and results from an analysis presented at the 2019 ASH Annual Meeting.
The 2nd annual Scientific and Medical Review Committee meeting was held in WA DC at Children’s National Hospital.
Riley Children’s Health at Indiana University Health is proud to become the only CureWorks member hospital in the Midwest. This unique collaboration will allow Riley oncologists and Indiana University School of Medicine researchers greater access to cutting-edge immunotherapy trials for pediatric oncology patients.
Children’s National Health System announces the opening of a chimeric antigen receptor (CAR) T-cell immunotherapy trial for pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Children’s National is now the second hospital in the country to offer the PLAT-05 trial after it first launched at Seattle Children’s.
Seattle Children’s Research Institute is launching a clinical trial that will examine a new kind of cancer-fighting treatment. The treatment is a type of CAR T immunotherapy, which reprograms a person’s immune cells to find and destroy cancer.
New cancer immunotherapies could revolutionize how we treat the disease, but for many children, those treatments are far out of reach.
Four academic children's hospitals have joined forces to create a research collaborative that will make it easier for their patients to access immunotherapy clinical trials and for their researchers to find good candidates for therapies.
Vancouver, BC — BC Children’s Hospital has joined CureWorks, an international collaborative of leading academic children’s hospitals focused on improving care for children with hard-to-treat cancers by expanding clinical trials and accelerating the development of leading-edge immunotherapy treatments.